Clarus Therapeutics Holdings, Inc. (CRXTQ)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2021 | 2020 |
|---|---|---|
| Operating Cash Flow | -43.78 Million | -41.58 Million |
| Net Income | -40.61 Million | 4.34 Million |
| Depreciation & Amortization | 25 Thousand | 18 Thousand |
| Deferred income taxes | -12.8 Million | -66.89 Million |
| Stock-based compensation | 668 Thousand | 825 Thousand |
| Change in working capital | -7.24 Million | 7.66 Million |
| Other non-cash items | 16.19 Million | 12.45 Million |
| Investing Cash Flow | -25 Thousand | -63 Thousand |
| Investments in PPE | -25 Thousand | -63 Thousand |
| Acquisitions | - | - |
| Investment purchases | - | - |
| Sales/Maturities of investments | - | - |
| Other Investing Activities | - | - |
| Financing Cash Flow | 62.99 Million | 47.22 Million |
| Debt repayment | - | -488 Thousand |
| Dividends payments | - | - |
| Common Stock Repurchased | - | - |
| Common Stock Issuance | 13.8 Million | - |
| Other Financing Activities | 49.19 Million | 47.7 Million |
| Accounts receivables | -1.94 Million | -4.4 Million |
| Accounts payables | 1.83 Million | 7.72 Million |
| Inventory | -8.35 Million | 1.1 Million |
| Other working capital | 1.21 Million | 3.23 Million |
| Cash at beginning of period | 7.23 Million | 1.65 Million |
| Cash at end of period | 26.41 Million | 7.23 Million |
| Capital Expenditure | -25 Thousand | -63 Thousand |
| Effect of forex changes on cash | - | - |
| Net cash flow / Change in cash | 19.18 Million | 5.57 Million |
| Free Cash Flow | -43.81 Million | -41.64 Million |
| Breakdown | 2022 Q2 | 2022 Q1 | 2021 FY | 2021 Q2 | 2020 FY |
|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - |
| Net Income | -10.69 Million | -14.87 Million | -40.61 Million | -18.11 Million | 4.34 Million |
| Depreciation & Amortization | 7000.00 | 7000.00 | 25 Thousand | 7000.00 | 18 Thousand |
| Deferred income taxes | - | - | -12.8 Million | - | -66.89 Million |
| Stock-based compensation | 451 Thousand | 432 Thousand | 668 Thousand | 177 Thousand | 825 Thousand |
| Change in working capital | -8.55 Million | 1.59 Million | -7.24 Million | -1.83 Million | 7.66 Million |
| Other non-cash items | 1.29 Million | -4.42 Million | 16.19 Million | 4.87 Million | 12.45 Million |
| Investing Cash Flow | -10 Thousand | -10 Thousand | -25 Thousand | -9000.00 | -63 Thousand |
| Investments in PPE | -10 Thousand | -10 Thousand | -25 Thousand | -9000.00 | -63 Thousand |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - |
| Financing Cash Flow | 27.53 Million | - | 62.99 Million | 17.81 Million | 47.22 Million |
| Debt repayment | -1.76 Million | - | - | - | -488 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | 13.8 Million | - | - |
| Other Financing Activities | 29.3 Million | - | 49.19 Million | 17.81 Million | 47.7 Million |
| Accounts receivables | -700 Thousand | -1.66 Million | -1.94 Million | -1 Million | -4.4 Million |
| Accounts payables | -5.56 Million | 111 Thousand | 1.83 Million | -2.72 Million | 7.72 Million |
| Inventory | -1.87 Million | -716 Thousand | -8.35 Million | -1.72 Million | 1.1 Million |
| Other working capital | -414 Thousand | 3.85 Million | 1.21 Million | 3.61 Million | 3.23 Million |
| Cash at beginning of period | 9.13 Million | 26.41 Million | 7.23 Million | 7.36 Million | 1.65 Million |
| Cash at end of period | 19.17 Million | 9.13 Million | 26.41 Million | 10.27 Million | 7.23 Million |
| Capital Expenditure | -10 Thousand | -10 Thousand | -25 Thousand | -9000.00 | -63 Thousand |
| Effect of forex changes on cash | 10 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 10.03 Million | -17.27 Million | 19.18 Million | 2.91 Million | 5.57 Million |
| Free Cash Flow | -17.51 Million | -17.27 Million | -43.81 Million | -14.9 Million | -41.64 Million |
000014
0990
2811
TD
0HMZ
3093